Nab-Paclitaxel Beats Docetaxel As First-Line Treatment For Metastatic Breast Cancer

[News]

Nab-paclitaxel (Abraxane for Injectable Suspension), at a dose of 150 mg/m2 weekly, improves overall survival (OS) to a much greater degree than conventional taxane monotherapy in women with previously untreated metastatic breast cancer (MBC), according to results of a phase II study released at the 34th Annual San Antonio Breast Cancer symposium (SABCS)...

More... (http://www.medicalnewstoday.com/articles/239054.php)